Neogene Therapeutics signs global license agreement with NCI for cancer treatment
The laboratory of Steven Rosenberg, chief of surgery at the NCI, discovered these TCRs. NCI is an institute of the National Institutes of Health (NIH). Neogene’s neoantigen TCR